Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.39 |
| ▸ | LMNA | P02545 | 7/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.39 |
| ▸ | USP2 | O75604 | 6/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.39 |
| ▸ | CASP1 | P29466 | 4/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1101081 | 0.92 | CNR2 (0.44) | HSD17B10MEN1KMT2AMAPTCYP3A4 | |
| SCHEMBL1100135 | 0.91 | ABL1 (0.43) | TRPV1 | |
| SCHEMBL1100645 | 0.91 | DGAT1 (0.46) | DGAT1ROCK2HSD17B10MEN1KMT2A | |
| SCHEMBL1099925 | 0.90 | KDM4E (0.46) | DGAT1ROCK2HSD17B10MEN1KMT2A | |
| SCHEMBL1100406 | 0.90 | MAPK1 (0.44) | DGAT1MAPTCYP1A2CYP2C19MAPK1 | |
| SCHEMBL1099248 | 0.89 | ROCK2 (0.43) | DGAT1ROCK2HSD17B10MEN1KMT2A | |
| SCHEMBL1101330 | 0.89 | DGAT1 (0.41) | DGAT1HSD17B10MEN1KMT2AMAPT | |
| Trifluoroacetic Acid SCHEMBL1100621 | 0.89 | ABL1 (0.42) | DGAT1TRPV1 | |
| SCHEMBL1100554 | 0.88 | TRPV1 (0.47) | DGAT1MAPTGRIN1GRIN2BUSP2 | |
| Trifluoroacetic Acid SCHEMBL1100565 | 0.87 | CNR1 (0.41) | DGAT1HSD17B10MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716272-B2 | N-(amino-heteroaryI)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | SANOFI (FR) | 2014-05-06 | — | — | US | disclosed |
| US-8716273-B2 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | SANOFI (FR) | 2014-05-06 | — | — | US | disclosed |
| EP-2125811-B1 | N-(AMINO-HETEROARYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDES DERIVATIVES, PREPARATION THEREOF AND THEIR USE IN THERAPY | SANOFI SA (FR) | 2013-05-29 | — | — | EP | disclosed |
| US-20120142669-A1 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | SANOFI-AVENTIS (FR) | 2012-06-07 | — | — | US | disclosed |
| US-20120142670-A1 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | SANOFI-AVENTIS (FR) | 2012-06-07 | — | — | US | disclosed |
| US-8153650-B2 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | SANOFI-AVENTIS (FR) | 2012-04-10 | — | — | US | disclosed |
| US-20100041634-A1 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | SANOFI-AVENTIS (FR) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142670-A1 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | ZYX, NQO2, PYCR1 | DGAT1 3777/4885ROCK2 424/4885HSD17B10 3313/4885 |
| US-20120142669-A1 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | ZYX, NQO2, PYCR1 | DGAT1 3777/4885ROCK2 424/4885HSD17B10 3313/4885 |
| US-20100041634-A1 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | ZYX, NQO2, PYCR1 | DGAT1 3777/4885ROCK2 424/4885HSD17B10 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.